Table SI. Tumour assessment type and utilization in the full analysis set (FAS)

Exploratory variable	*n* (% of total)[a]
Method of tumour response evaluation (total number of assessments[b]=393)	
Clinical assessment	367 (93.4)
Imaging assessment	85 (21.6)
Histological assessment	31 (7.9)
Missing	12 (3.1)
BCC therapy before vismodegib therapy[c] (patients with previous therapy=35)	
Surgery	29 (82.9)
Surgery, radiotherapy	3 (8.6)
Surgery, local therapy	1 (2.9)
Surgery, radiotherapy, local therapy	1 (2.9)
Surgery, local therapy, medication	1 (2.9)
BCC therapy after vismodegib therapy[d] (patients with therapy afterwards[e]=24)	
Surgery	11 (45.8)
Hedgehog inhibitor	8 (33.3)
PD-1 inhibitor	4 (16.7)
Local therapy	1 (4.2)
Radiotherapy	1 (4.2)
Other systemic therapy	1 (4.2)
Reason for treatment interruption (total number of interruptions=56)	
Other than the predefined reasons	33 (58.9)
Patient's request	11 (19.6)
Toxicity	11 (19.6)
Progressive disease	1 (1.8)
Reason for treatment discontinuation (patients with confirmed discontinuation=49)	
Other than the predefined reasons	23 (46.9)
Progressive disease	11 (22.4)
Patient's request	10 (20.4)
Toxicity	5 (10.2)
Treatment duration (total patients=53), months, mean (SD)	11.2 (12.84)
Median (range)	6 (0–56)
Time to first interruption[f] (patients with an interruption=25), months, mean (SD)	3.1 (2.79)
Median (range)	2 (0–13)
Number of interruption(s) per patient (total patients=53), mean (SD)	1.1 (1.86)
Median (range)	0 (0–10)
Duration of interruption(s)[g] (total number of interruptions=56), days, mean (SD)	66.4 (104.18)
Median (range)	37 (1–576)
Treatment duration excl. interruption(s)[g] (total patients=53), months, mean (SD)	8.9 (10.87)
Median (range)	6 (0–56)

[a]The % of total was calculated from the respective total displayed for each variable. [b]While multiple types of assessments per patient could have been carried out on the same day, the total number of assessments counts these as one. [c]BCC therapy prior to vismodegib therapy was collected as a categorical variable pre-specified in the eCRF with the following categories: medication, surgery, radiotherapy, local therapy, no previous treatment. [d]BCC therapy after vismodegib therapy was collected as a categorical variable pre-specified in the eCRF with the following categories: PD-1, hedgehog, other systemic therapy, surgery, local therapy, radiotherapy. [e]Patient count is not equal to therapy count, as 1 patient could have received multiple therapies. [f]For 1 patient only the year of the interruption was available, resulting in a negative time to first interruption. In this case, the time to first interruption was set to 0. [g]For 5 interruptions with missing end date, the median length of interruptions observed in this study was assumed (37 days).
BCC: basal cell carcinoma; PD-1: programmed cell death protein 1; SD: standard deviation.